en · de · es
sr9009-notes.peptides1004.com › News › Sr9009 Background And Mechanism — Complete Guide

Sr9009 Background And Mechanism — Complete Guide

By Editorial Desk · published 2026-04-08 · last reviewed 2026-05-31 · News

This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-05-31. Anything still debated is marked as such rather than presented as settled.

SR9009 Background and Mechanism

Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.

In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.

Detection, Regulation, and Misconceptions

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small-molecule REV-ERB agonistNot a hormone or natural product
Primary targetsREV-ERBα and REV-ERBβNuclear receptors involved in circadian and metabolic regulation
AppearanceWhite to off-white solidTypical for purified research samples
SolubilitySoluble in DMSO and ethanol; low water solubilityLaboratory solubility depends on solvent and purity
Common synonymsSR9009; StenabolicStenabolic is a colloquial name, not a formal chemical name

Background and Receptor Mechanism

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Related pages on this site

Analytical Detection and Laboratory Handling

Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Background and Mechanism of SR9009

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Analytical Detection and Regulatory Status

Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Reference notes

The 23S rRNA is a 2,904 nucleotide long (in E. coli) component of the large subunit (50S) of the bacterial/archean ribosome and makes up the peptidyl transferase center (PTC). The 23S rRNA is divided into six secondary structural domains titled I-VI, with the corresponding 5S rRNA being considered domain VII. The ribosomal peptidyl transferase activity resides in domain V of this rRNA, which is also the most common binding site for antibiotics that inhibit translation, making it a target for ribosomal engineering. A well-known member of this antibiotic class, chloramphenicol, acts by inhibiting peptide bond formation, with recent 3D-structural studies showing two different binding sites depending on the species of ribosome. Numerous mutations in domains of the 23S rRNA with Peptidyl transferase activity have resulted in antibiotic resistance. 23S rRNA genes typically have higher sequence variations, including insertions and/or deletions, compared to other rRNAs. The eukaryotic homolog of the 23S LSU rRNA is the 28S ribosomal RNA, with a region filled by the 5.8S ribosomal RNA.

Despite being formally abolished in the 1960s, slavery in Yemen remains a significant issue exacerbated by ongoing conflict and socio-economic instability. An estimated 85,000 people remaining enslaved as of 2022. The Iran-backed Houthi militias have been accused of reinstating traditional slavery systems. Reports indicate that over 1,800 Yemenis have been forced into servitude by prominent Houthi leaders, with the Houthis dividing society into hierarchical classes of masters and slaves.

Flay opened a second Mesa Grill at Caesars Palace in Las Vegas in 2004, and in 2005 he opened Bar Americain, an American Brasserie, in Midtown Manhattan. He continued to expand his restaurants by opening Bobby Flay Steak in the Borgata Hotel Casino & Spa in Atlantic City, New Jersey. This was followed by a third Mesa Grill in the Bahamas, located in The Cove at Atlantis Paradise Island, which opened on March 28, 2007. The Las Vegas Mesa Grill earned Flay his only Michelin Star in 2008, which was taken away in the 2009 edition. Michelin did not publish a 2010 or 2011 Las Vegas edition, so the star could not be re-earned. Bolo Bar & Restaurant closed its doors on December 31, 2007, to make way for a condominium. Aside from his restaurants and television shows, Flay has been a master instructor and visiting chef at the French Culinary Institute. Although he is not currently teaching classes, he occasionally visits when his schedule permits. Flay established the Bobby Flay Scholarship in 2003. This full scholarship to the French Culinary Institute is awarded annually to a student in the Long Island City Culinary Arts Program. Flay personally helps select the awardee each year. Flay opened his first Bobby's Burger Palace (BBP) at the Smith Haven Mall in Lake Grove, Long Island, on July 15, 2008. At its peak, BBP had nineteen locations in eleven states and the District of Columbia. The original Mesa Grill in New York closed in September 2013 following a proposed rent increase by the landlord.

== Additional references == Bodenhamer, David J; Barrows, Robert G, eds. (1994). The Encyclopedia of Indianapolis. Bloomington and Indianapolis: Indiana University Press. ISBN 978-0-253-31222-8. Kahn, E. J. (1975). All In A Century: The First 100 Years of Eli Lilly and Company. West Cornwall, CT: Eli Lilly and Company. OCLC 5288809. Podczeck, Fridrun; Jones, Brian E. (2004). Pharmaceutical Capsules. Chicago: Pharmaceutical Press. ISBN 978-0-85369-568-4. Price, Nelson (1997). Indiana Legends: Famous Hoosiers From Johnny Appleseed to David Letterman. Indianapolis: Guild Press of Indiana. ISBN 978-1-57860-006-9. Taylor Jr., Robert M.; Stevens, Errol Wayne; Ponder, Mary Ann; Brockman, Paul (1989). Indiana: A New Historical Guide. Indianapolis: Indiana Historical Society. p. 481. ISBN 978-0-87195-048-2. Tobias, Randall; Tobias, Todd (2003). Put the Moose on the Table: Lessons in Leadership from a CEO's Journey through Business and Life. Indiana University Press. ISBN 978-0-253-11011-4. Weintraut, Linda; Nolan, Jane R. "The Secret Life of Building 314". Traces of Indiana and Midwestern History. 8 (3). Indianapolis: Indiana Historical Society: 16–27.

Epidermal growth factor (EGF) is a protein that stimulates cell growth and differentiation by binding to its receptor, EGFR. Human EGF is 6-kDa and has 53 amino acid residues and three intramolecular disulfide bonds. EGF was originally described as a secreted peptide found in the submaxillary glands of mice and in human urine. EGF has since been found in many human tissues, including platelets, submandibular gland (submaxillary gland), and parotid gland. Initially, human EGF was known as urogastrone.

Sources: en.wikipedia.org

Notes from published material

In January 2026, the American Civil Liberties Union, Center for Constitutional Rights, and Jonathan Hafetz filed a federal lawsuit against the United States government on behalf of the families of two people from Las Cuevas, Trinidad and Tobago who were killed in a strike on 14 October 2025. The lawsuit alleged that the strikes were "premeditated and intentional killings" that "lack any plausible legal justification" and were "simply murder, ordered at the highest levels of government and obeyed by military officers in the chain of command."

=== Wild-type (ATTRwt-CM) === This type has no mutations in the TTR gene but TTR deposits still form in the heart and other tissues. Males are more commonly affected, at ages over 70 years. Carpal tunnel syndrome may form as well as amyloid deposits in the carpal tunnel causing compression of the median nerve. Amyloid deposits in the carpal tunnel or other ligaments (causing tendon rupture) or the spinal canal causing spinal stenosis may precede the development of heart failure by 10-15 years. Wild type ATTR cardiac amyloidosis (and the genetic variant) can be diagnosed with cardiac nuclear scintigraphy to visualize amyloid deposits in the heart walls. Serum free light chains, serum and urine electrophoresis with immunofixation can rule out AL amyloidosis. If the diagnosis is unclear, a biopsy may be obtained. Biopsy with histological evaluation can rule out light chain and genetic testing can rule out familial subtypes. This type is often misdiagnosed. However, greater use of cardiac magnetic resonance has increased the rate of diagnosis. The severity of the disease tends to be less than the light chain and familial variants. This is due to the amount of time that it takes to accumulate the amyloid depositions being longer in the wild-type variant.

If there have not been out of tolerance temperatures for critical times, continue to use the shipment, without special inspection If potentially damaging temperature hazards have occurred, thoroughly inspect the shipment for damage or degradation. Possibly accelerate sale and use because of reduced shelf life. The consignee may negotiate with the carrier or shipper or even choose to reject a shipment where sensors indicate severe temperature history The time of the temperature extreme, or GPS tracking, may be able to determine the location of the infraction to direct appropriate corrective action. Multiple replicate shipments of data loggers are also used to compare modes of shipment (routes, vendors) and to develop composite data to be used in package testing protocols. There are many brands and models of data loggers. Most are a connectable device that must be plugged into a computer to extract the data that the logger has logged.

The use of both "ambient" and non-Saccharomyces wild yeasts carries both potential benefits and risk. Some winemakers feel that the use of resident/indigenous yeast helps contribute to the unique expression of terroir in the wine. In wine regions such as Bordeaux, classified and highly regarded estates will often tout the quality of their resident "chateau" strains. To this extent, wineries will often take the leftover pomace and lees from winemaking and return them to the vineyard to be used as compost in order to encourage the sustained presence of favorable strains. But compared to inoculated yeast, these ambient yeasts hold the risk of having a more unpredictable fermentation. Not only could this unpredictability include the presence of off-flavors/aromas and higher volatile acidity but also the potential for a stuck fermentation if the indigenous yeast strains are not vigorous enough to fully convert all the sugars. It is virtually inevitable that non-Saccharomyces wild yeast will have a role in beginning the fermentation of virtually every wine but for the wineries that choose to allow these yeasts to continue fermenting versus minimizing their influence do so with the intent of enhancing complexity through bio-diversity. While these non-Saccharomyces ferment glucose and fructose into alcohol, they also have the potential to create other intermediates that could influence the aroma and flavor profile of the wine. Some of these intermediates could be positive, such as phenylethanol, which can impart a rose-like aroma.

NMNH (Dihydronicotinamide mononucleotide), also known as reduced nicotinamide mononucleotide. Both NMNH and NMN increase NAD+ levels in the body. NAD+ is a universal coenzyme that plays vital roles in nearly all living organisms functioning in various biological processes such as metabolism, cell signaling, gene regulation, and DNA repair.

Sources: en.wikipedia.org

Background from the literature

=== Lily Tao === Lily Tao (played by an uncredited child actress in series 1, Neve Bonner in series 2-3, and Serrana Su-Ling Bliss in series 4) is one of Eric and Candice's daughters, alongside her twin sister Lara. In series 1, Harper spots Eric playing with his daughters in a grocery store after being suspended from Pierpoint. In series 2, Eric returns home from a trip to New York to kiss his children goodnight, having secretly cheated on their mother with his ex-girlfriend Holly during the trip. In series 3, Eric, divorced from Candice, brings his daughters to Pierpoint on the day of the tumultuous IPO of green-energy company Lumi. In series 4, Lily is older and attending private school in England, while Eric is retired and living in the United States, estranged from his family. His family office, LilyLara, is named after his daughters. Eric returns to London to partner with Harper on a short-only hedge fund, SternTao, and allows Lily to visit the hotel serving as their office, blurring the work-life boundary Harper strives to maintain with Eric. Eric later learns Lily has been expelled from school for running a catfishing scheme on another student, and reflects on how his daughter has inherited his own cruelty, while lamenting his own inability to properly love his children. He comforts Lily and allows her and Candice to stay in his suite, but visits a prostitute that same night.

=== Beer–Lambert law === The roots of the term absorbance are in the Beer–Lambert law (or Beer's law). As light moves through a medium, it will become dimmer as it is being "extinguished". Pierre Bouguer recognized that this extinction (now often called attenuation) was not linear with distance traveled through the medium, but related to what is now referred to as an exponential function. If

adenosine triphosphate (ATP) A nucleoside triphosphate consisting of adenosine attached to three consecutive phosphate groups via high-energy ester bonds. The conversion of ATP into ADP or AMP via hydrolysis of these phosphates releases energy which is used to drive the majority of energy-consuming chemical reactions in all living cells, and hence ATP functions as a universal and ubiquitous energy carrier which is often referred to as the "molecular currency" of intracellular metabolism. It is continuously regenerated via phosphorylation of ADP and AMP by enzymes such as ATP synthase. Like other nucleoside triphosphates, it also serves as a precursor for nucleic acid synthesis.

On 8 June 1936, the Matignon Accords granted the 40 hours workweek to the workers, as well as right of collective bargaining, right of strike action, and dismantled all laws preventing organization of trade-unions. Elsewhere, democratic socialists remained hostile to Stalinism and rejected the popular front strategy. For example, the Communist Party leader Earl Russell Browder offered to be Thomas' running mate on a joint Socialist Party–Communist Party ticket, but Thomas rejected this overture. After the election of a Popular Front government in Spain in 1936 a fascist military revolt led to the Spanish Civil War. Democratic socialists from around the world fought on the side of the Republican government, for instance in the ILP Contingent of the International Brigades, in which George Orwell served. The crisis in Spain also brought down Blum's Popular Front government in France and ultimately the Popular Fronts were not able to prevent the spread of fascism or the aggressive plans of the fascist powers.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.

How does SR9009 work?

It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.

Is SR9009 proven to improve human performance?

No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.

Is SR9009 legal to buy?

Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.

Network